Entity
Description
  • Value proposition

    Developing the next generation of complement medicines

    Complement Therapeutics GmbH (CTx) is an early-stage biotechnology company focused on the research and development of novel therapeutics for complement-mediated diseases. The Company is a spinout from the University of Manchester and is based on the pioneering research of its founders into novel targets within the complement cascade.

    Our lead investigational product (CTx001) is being evaluated as a potential gene therapy for dry age-related macular degeneration/geographic atrophy, a leading cause of blindness. Additional programmes will evaluate potential therapeutic opportunities in other complement-mediated conditions.

    The Company is also developing a unique quantification methodology, the Complement Precision Medicine (CPM) platform, to enable quantification of over 30 complement cascade proteins enabling more precise diagnosis and monitoring of disease.

Corporate interactions BETA
Corporate TypeTweets Articles
UK Atomic Energy Authority
UK Atomic Energy Authority
Research, National and local authorities
UK Atomic Energy Authority
Research, National and local authorities
Other

12 May 2024


Gimv
Gimv
Financial Services
Gimv
Financial Services
Other

30 Apr 2023


Nasdaq
Nasdaq
Finance, Financial Services
Nasdaq
Finance, Financial Services
Other

30 Apr 2023


Similar entities
Loading...
Loading...
Social network dynamics